Haploidentical Hematopoietic Cell Transplantation for Children With Hematologic Malignancies and Myelodysplasia

Running, not enrolling · Phase 1/Phase 2

Conditions studied: Myelodysplasia, Hematologic Malignancy

In brief

This is a Phase I/II study designed to evaluate the kinetics of hematopoietic reconstitution and the incidence of acute chronic GVHD after partially matched related donor hematopoietic cell transplantation using an αβTCR/CD19+ cell depleted graft.

Key facts

Study ID

NCT03431090

Run by

Nationwide Children's Hospital

People needed

20

Starts

2018-03-02

Expected to finish

2026-12-01

Last updated by the study team

2026-04-03

Who can join

Age: any, up to 30. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Patient lacks an HLA matched sibling donor.
• Meets criteria nonhematopoietic organ function according to NCH BMT SOP09.
• If subjects have received a first HCT, they must be eligible for a second HCT if their disease has recurred.
• High resolution HLA and KIR typing
• The subject cannot have an active untreated infection. Viremia by PCR analysis is not considered an active infection but may require immediate viral prophylaxis. Patients with possible fungal infections must have had at least 2 weeks of appropriate anti- fungal therapy and be asymptomatic.
• Negative pregnancy test for females ≥11 years of age or post- menarche.
• Sexually active males and females of childbearing potential must agree to use a form of contraception considered effective and medically acceptable by the Investigator. (Non-childbearing potential defined as pre-menarche, greater than one year post-menopausal or surgically sterilized).
• Subjects must be ≤30 years at the time of consent.
• Signed consent by parent/guardian and assent if appropriate for subjects < 18 years of age. Signed consent by patient/subject if ≥18 years of age.

You may not qualify if…

• Patient does not have a suitable donor who is willing and able (meets donor criteria).
• Patient has donor-specific anti-HLA antibodies at the time of enrollment
• Patient reports a history of allergic reactions to murine protein
• Donor Eligibility:
• The donor must be ≥18 years of age at the time of the informed consent conference.
• The donor must be a related donor
• The donor will be evaluated according to the current NCH BMT SOP 04 and must meet all criteria.
• The donor must be able and willing to undergo G-CSF mobilization and stem cell apheresis.
• The patient does not have donor specific anti-HLA antibodies

Where it is running

• Nationwide Children's Hospital — Columbus, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.